Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2011

View Archived Issues

Heroin-like immunoconjugate protects against addiction

Privigen shows promise to treat Alzheimer's disease in preclinical test

Confirmatory phase III trial to assess Gammagard Liquid in mild to moderate Alzheimer's disease

New biomarker to differentiate benign and dangerous pancreatic cyst neoplasms

New histamine H3 receptor antagonists prepared at Takeda

Merck KGaA presents novel sphingosine kinase 1 inhibitors

Poxel discloses new AMPK activators

Novel c-Akt inhibitors synthesized at ArQule

New GLP-1 analogues and derivatives disclosed by Novo Nordisk

Bristol-Myers Squibb synthesizes novel HCV NS5A inhibitors

New therapeutic strategy identified for inflammation and autoimmune conditions

Kowa begins phase III trial of K-115 in Japan

Molecular Response and SuperGen enter translational oncology agreement

Lupin and Medicis enter agreement for formulating multiple therapeutics

Merck & Co. submits MAA for ridaforolimus in Europe

Vanda and Biotoscana Farma enter license agreement for Fanapt in Argentina

FDA places clinical hold on phase III trials of Insmed amikacin product

Teva and Active Biotech report initial results from BRAVO trial of laquinimod

Phase IIb trial of ponesimod in MS meets primary endpoint

MM-398 receives orphan drug status in pancreatic cancer

Enrollment initiated in phase II/III study of CF-101

Enrollment begins in phase III Kiobrina trial in preterm infants

Cubist Pharmaceuticals commences pivotal phase III trial of CXA-201

NYU Langone Medical Center receives grant to conduct comparative trial in coronary artery disease

NICE issues final guidance on recommendation of Ozurdex for macular edema due to RVO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...